"Drotrecogin alfa (activated) in sepsis: Initial experience with patient selection, cost, and clinical outcomes." by Thomas Higgins, MD

Selected Works of William T. McGee MD

Follow Contact

Article

Drotrecogin alfa (activated) in sepsis: Initial experience with patient selection, cost, and clinical outcomes.

All Scholarly Works

Thomas Higgins, MD, Baystate Health
Jay Steingrub, MD, Baystate Health
Mark Tidswell, MD, Baystate Health
William McGee, MD, Baystate Health
Gary Tereso, Baystate Health

Link

Document Type

Article, Peer-reviewed

Publication Date

11-1-2005

Disciplines

Medicine and Health Sciences

Abstract

During a 1-year period, the authors examined clinical experience with drotrecogin alfa, activated for sepsis in a 24-bed medical-surgical intensive care unit. Drotrecogin alfa, activated was administered 46 times to 44 patients (3% of all intensive care u

Publication ISSN

0195-9131

Citation Information

J Intensive Care Med. 2005 Nov-Dec;20(6):339-45.